Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort.
Hayashi N, Fukai J, Nakatogawa H, Kawaji H, Yoshioka E, Kodama Y, Nakajo K, Uda T, Naito K, Kijima N, Okita Y, Kagawa N, Takahashi Y, Hashimoto N, Arita H, Takano K, Sakamoto D, Iida T, Arakawa Y, Kawauchi T, Sonoda Y, Mitobe Y, Ishibashi K, Matsuda M, Achiha T, Tomita T, Nonaka M, Hara K, Takebe N, Tsuzuki T, Nakajima Y, Ohue S, Nakajima N, Watanabe A, Inoue A, Umegaki M, Kanematsu D, Katsuma A, Sumida M, Shofuda T, Mano M, Kinoshita M, Mori K, Nakao N, Kanemura Y. Hayashi N, et al. Among authors: takebe n. Acta Neuropathol Commun. 2024 Jul 27;12(1):120. doi: 10.1186/s40478-024-01808-w. Acta Neuropathol Commun. 2024. PMID: 39061104 Free PMC article.
Correction: Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort.
Hayashi N, Fukai J, Nakatogawa H, Kawaji H, Yoshioka E, Kodama Y, Nakajo K, Uda T, Naito K, Kijima N, Okita Y, Kagawa N, Takahashi Y, Hashimoto N, Arita H, Takano K, Sakamoto D, Iida T, Arakawa Y, Kawauchi T, Sonoda Y, Mitobe Y, Ishibashi K, Matsuda M, Achiha T, Tomita T, Nonaka M, Hara K, Takebe N, Tsuzuki T, Nakajima Y, Ohue S, Nakajima N, Watanabe A, Inoue A, Umegaki M, Kanematsu D, Katsuma A, Sumida M, Shofuda T, Mano M, Kinoshita M, Mori K, Nakao N, Kanemura Y. Hayashi N, et al. Among authors: takebe n. Acta Neuropathol Commun. 2024 Oct 1;12(1):155. doi: 10.1186/s40478-024-01863-3. Acta Neuropathol Commun. 2024. PMID: 39354603 Free PMC article. No abstract available.
Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study.
Reinhold WC, Marangoni E, Elloumi F, Montagne R, Varma S, Wang Y, Rezai K, Morriset L, Dahmani A, El Botty R, Huguet L, Mizunuma M, Takebe N, Huguet S, Luna A, Pommier Y. Reinhold WC, et al. Among authors: takebe n. Cancer Res Commun. 2025 Feb 1;5(2):375-388. doi: 10.1158/2767-9764.CRC-24-0435. Cancer Res Commun. 2025. PMID: 39932272 Free PMC article.
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma.
Patel SP, Cano-Linson E, Chae YK, Schokrpur S, Lao CD, Powers BC, Victor AI, Onitilo AA, Shin S, Takebe N, Threlkel S, McLeod CM, Chen HX, Sharon E, Othus M, Ryan CW, Blanke CD, Kurzrock R. Patel SP, et al. Among authors: takebe n. NPJ Precis Oncol. 2025 Jan 24;9(1):24. doi: 10.1038/s41698-024-00798-1. NPJ Precis Oncol. 2025. PMID: 39856213 Free PMC article.
Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma.
Lee EQ, Alexander BM, Romo CG, Supko JG, Agar NYR, Talebi Z, Ahluwalia MS, Desai AS, Dietrich J, Kaley TJ, Peereboom DM, Gantchev J, Baquer G, Santagata S, Takebe N, Desideri S, Fisher JD, Sims M, Ye X, Ligon KL, Nabors LB, Grossman SA, Wen PY. Lee EQ, et al. Among authors: takebe n. Clin Cancer Res. 2025 Mar 17;31(6):983-992. doi: 10.1158/1078-0432.CCR-24-2311. Clin Cancer Res. 2025. PMID: 39820282 Clinical Trial.
Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U.
Zauderer MG, Jegede O, Jackman DM, Zwiebel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Takebe N, Huang R, Carrillo JA, Brenner AJ, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Zauderer MG, et al. Among authors: takebe n. JCO Precis Oncol. 2024 Dec;8:e2400327. doi: 10.1200/PO.24.00327. Epub 2024 Dec 18. JCO Precis Oncol. 2024. PMID: 39693587 Clinical Trial.
202 results